Reported Earnings • May 20
First quarter 2026 earnings released: JP¥4.01 loss per share (vs JP¥9.03 loss in 1Q 2025) First quarter 2026 results: JP¥4.01 loss per share (improved from JP¥9.03 loss in 1Q 2025). Net loss: JP¥238.0m (loss narrowed 45% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. New Risk • Mar 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue is less than US$1m (JP¥128m revenue, or US$813k). Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (JP¥7.42b market cap, or US$47.2m). Reported Earnings • Feb 16
Full year 2025 earnings released: JP¥17.44 loss per share (vs JP¥18.54 loss in FY 2024) Full year 2025 results: JP¥17.44 loss per share. Net loss: JP¥937.0m (loss widened 16% from FY 2024). Duyuru • Feb 13
MedRx Co., Ltd, Annual General Meeting, Mar 27, 2026 MedRx Co., Ltd, Annual General Meeting, Mar 27, 2026. Duyuru • Dec 27
MedRx Co., Ltd to Report Fiscal Year 2025 Results on Feb 13, 2026 MedRx Co., Ltd announced that they will report fiscal year 2025 results on Feb 13, 2026 Duyuru • Oct 01
MedRx Co., Ltd to Report Q3, 2025 Results on Nov 14, 2025 MedRx Co., Ltd announced that they will report Q3, 2025 results on Nov 14, 2025 New Risk • Aug 25
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.2b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue is less than US$1m (JP¥44m revenue, or US$298k). Minor Risks Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (JP¥6.38b market cap, or US$43.3m). New Risk • Aug 14
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥1.2b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.2b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue is less than US$1m (JP¥44m revenue, or US$300k). Minor Risk Market cap is less than US$100m (JP¥5.18b market cap, or US$35.3m). New Risk • Aug 10
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: JP¥44m (US$298k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (JP¥44m revenue, or US$298k). Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (JP¥3.42b market cap, or US$23.1m). New Risk • Jul 09
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.9% average weekly change). Minor Risks Revenue is less than US$5m (JP¥259m revenue, or US$1.8m). Market cap is less than US$100m (JP¥3.70b market cap, or US$25.2m). Duyuru • Jul 02
MedRx Co., Ltd to Report Q2, 2025 Results on Aug 08, 2025 MedRx Co., Ltd announced that they will report Q2, 2025 results on Aug 08, 2025 Duyuru • Apr 16
MedRx Co., Ltd announced that it has received ¥0.8309 million in funding On April 16, 2025, MedRx Co., Ltd closed the transaction. New Risk • Apr 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Shareholders have been diluted in the past year (23% increase in shares outstanding). Revenue is less than US$5m (JP¥257m revenue, or US$1.8m). Market cap is less than US$100m (JP¥2.71b market cap, or US$18.5m). Duyuru • Mar 28
MedRx Co., Ltd to Report Q1, 2025 Results on May 09, 2025 MedRx Co., Ltd announced that they will report Q1, 2025 results on May 09, 2025 Duyuru • Mar 25
MedRx Co., Ltd announced that it expects to receive ¥0.8309 million in funding MEDRx Co., Ltd. announced a private placement to issue 118,700 units 32nd Series of Stock Acquisition Rights at an issue price of ¥7 per right for gross proceeds of ¥830,900 on March 25, 2025. The transaction will include participation from new investor Long Corridor Alpha Opportunities Master Fund. The transaction has been approved by shareholders, expected to close on April 16, 2025. The initial exercise price will be ¥86. The period will be from April 17, 2025 (inclusive) to April 23, 2026 (inclusive). The allocation will be made through a third-party allocation as follows: LCAO 94,960 units MAP 246 23,740 units. The company has disclosed the issue expenses of ¥12,000,000 and net proceeds of ¥1,009,650,900, total amount of payment of ¥1,021,650,900. Reported Earnings • Feb 16
Full year 2024 earnings released: JP¥18.54 loss per share (vs JP¥26.80 loss in FY 2023) Full year 2024 results: JP¥18.54 loss per share (improved from JP¥26.80 loss in FY 2023). Revenue: JP¥257.0m (up JP¥228.0m from FY 2023). Net loss: JP¥806.0m (loss narrowed 14% from FY 2023). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Duyuru • Feb 14
MedRx Co., Ltd, Annual General Meeting, Mar 28, 2025 MedRx Co., Ltd, Annual General Meeting, Mar 28, 2025. Duyuru • Jan 03
MedRx Co., Ltd to Report Fiscal Year 2024 Results on Feb 14, 2025 MedRx Co., Ltd announced that they will report fiscal year 2024 results on Feb 14, 2025 Duyuru • Aug 31
MedRx Co., Ltd to Report Q3, 2024 Results on Nov 08, 2024 MedRx Co., Ltd announced that they will report Q3, 2024 results on Nov 08, 2024 Duyuru • Jun 28
MedRx Co., Ltd to Report Q2, 2024 Results on Aug 09, 2024 MedRx Co., Ltd announced that they will report Q2, 2024 results on Aug 09, 2024 Reported Earnings • May 13
First quarter 2024 earnings released: JP¥3.33 loss per share (vs JP¥9.59 loss in 1Q 2023) First quarter 2024 results: JP¥3.33 loss per share (improved from JP¥9.59 loss in 1Q 2023). Net loss: JP¥128.0m (loss narrowed 56% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Duyuru • Apr 05
MedRx Co., Ltd to Report Q1, 2024 Results on May 10, 2024 MedRx Co., Ltd announced that they will report Q1, 2024 results on May 10, 2024 Duyuru • Feb 11
MedRx Co., Ltd, Annual General Meeting, Mar 28, 2024 MedRx Co., Ltd, Annual General Meeting, Mar 28, 2024. Duyuru • Feb 06
MedRx Co., Ltd announced that it has received ¥1.9076 million in funding from Evolution Capital Management LLC On February 5, 2024, MedRx Co., Ltd, closed the transaction. Duyuru • Dec 28
MedRx Co., Ltd to Report Fiscal Year 2023 Results on Feb 09, 2024 MedRx Co., Ltd announced that they will report fiscal year 2023 results on Feb 09, 2024 New Risk • Oct 24
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 54% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.3b free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Revenue is less than US$1m (JP¥56m revenue, or US$374k). Minor Risk Market cap is less than US$100m (JP¥5.14b market cap, or US$34.4m). Duyuru • Oct 05
MedRx Co., Ltd to Report Q3, 2023 Results on Nov 10, 2023 MedRx Co., Ltd announced that they will report Q3, 2023 results on Nov 10, 2023 New Risk • Aug 17
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥1.3b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.3b free cash flow). Revenue is less than US$1m (JP¥56m revenue, or US$384k). Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Shareholders have been diluted in the past year (43% increase in shares outstanding). Market cap is less than US$100m (JP¥6.27b market cap, or US$43.0m). Reported Earnings • Aug 12
Second quarter 2023 earnings released: JP¥5.60 loss per share (vs JP¥7.52 loss in 2Q 2022) Second quarter 2023 results: JP¥5.60 loss per share. Net loss: JP¥191.0m (loss widened 3.2% from 2Q 2022). Duyuru • Jun 28
MedRx Co., Ltd to Report Q2, 2023 Results on Aug 10, 2023 MedRx Co., Ltd announced that they will report Q2, 2023 results on Aug 10, 2023 Reported Earnings • May 17
First quarter 2023 earnings released: JP¥9.59 loss per share (vs JP¥7.97 loss in 1Q 2022) First quarter 2023 results: JP¥9.59 loss per share (further deteriorated from JP¥7.97 loss in 1Q 2022). Net loss: JP¥290.0m (loss widened 48% from 1Q 2022). Revenue is forecast to grow 64% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 31
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: JP¥43.80 loss per share. Net loss: JP¥1.11b (loss widened 4.9% from FY 2021). Revenue missed analyst estimates by 82%. Earnings per share (EPS) also missed analyst estimates by 7.4%. Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Pharmaceuticals industry in Japan. Reported Earnings • Feb 12
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: JP¥43.80 loss per share. Net loss: JP¥1.11b (loss widened 4.9% from FY 2021). Revenue missed analyst estimates by 82%. Earnings per share (EPS) also missed analyst estimates by 7.4%. Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Pharmaceuticals industry in Japan. Duyuru • Feb 12
MedRx Co., Ltd, Annual General Meeting, Mar 29, 2023 MedRx Co., Ltd, Annual General Meeting, Mar 29, 2023. Duyuru • Dec 28
MedRx Co., Ltd to Report Fiscal Year 2022 Results on Feb 10, 2023 MedRx Co., Ltd announced that they will report fiscal year 2022 results on Feb 10, 2023 Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 7 highly experienced directors. 1 independent director (6 non-independent directors). Independent External Director Kunio Iwatani was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Nov 13
Third quarter 2022 earnings released: JP¥10.32 loss per share (vs JP¥9.21 loss in 3Q 2021) Third quarter 2022 results: JP¥10.32 loss per share (further deteriorated from JP¥9.21 loss in 3Q 2021). Net loss: JP¥254.0m (loss widened 25% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. Duyuru • Sep 28
MedRx Co., Ltd to Report Q3, 2022 Results on Nov 11, 2022 MedRx Co., Ltd announced that they will report Q3, 2022 results on Nov 11, 2022 Duyuru • Aug 24
MedRx Co., Ltd announced that it expects to receive ¥3.904 million in funding MedRx Co., Ltd announced a private placement of 61,000 series 24 warrants at a price of ¥64 each for gross proceeds of ¥3,904,000. The series 24 warrants at exercisable at a minimum price of ¥64. Reported Earnings • Aug 12
Second quarter 2022 earnings released: JP¥7.52 loss per share (vs JP¥10.61 loss in 2Q 2021) Second quarter 2022 results: JP¥7.52 loss per share (up from JP¥10.61 loss in 2Q 2021). Net loss: JP¥185.0m (loss narrowed 12% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. Duyuru • May 30
MedRx Co., Ltd to Report Q2, 2022 Results on Aug 10, 2022 MedRx Co., Ltd announced that they will report Q2, 2022 results on Aug 10, 2022 Reported Earnings • May 19
First quarter 2022 earnings released: JP¥7.97 loss per share (vs JP¥13.32 loss in 1Q 2021) First quarter 2022 results: JP¥7.97 loss per share (up from JP¥13.32 loss in 1Q 2021). Net loss: JP¥196.0m (loss narrowed 25% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 7 highly experienced directors. 1 independent director (6 non-independent directors). Independent External Director Kunio Iwatani was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Duyuru • Apr 08
MedRx Co., Ltd to Report Q1, 2022 Results on May 13, 2022 MedRx Co., Ltd announced that they will report Q1, 2022 results on May 13, 2022 Duyuru • Feb 12
MedRx Co., Ltd, Annual General Meeting, Mar 30, 2022 MedRx Co., Ltd, Annual General Meeting, Mar 30, 2022. Duyuru • Jun 04
MedRx Co., Ltd announced that it has received ¥552.489 million in funding from Macquarie Bank Limited, Investment Arm On June 3, 2021, MedRx Co., Ltd (TSE:4586) closed the transaction. The company issued 40 Series 2 Unsecured Bonds at a price of ¥13,750,000 for gross proceeds of ¥550,000,000. Duyuru • May 19
MedRx Co., Ltd announced that it expects to receive ¥2.489 million in funding from Macquarie Bank Limited, Investment Arm MedRx Co., Ltd (TSE:4586) announced a private placement of 30,000 series 20 warrants at a price of ¥57 each for gross proceeds of ¥1,710,000 and 19,000 series 21 warrants at a price of ¥41 per share for gross proceeds of ¥779,000? for aggregate gross proceeds of ¥2,489,000 on May 18, 2021. The company will issue securities through third party allotment method to Macquarie Bank Limited, Investment Arm. The series 20 warrants at exercisable at a minimum price of ¥223 and series 21 Warrants for ¥330. Reported Earnings • Apr 04
Full year 2020 earnings released: JP¥68.57 loss per share (vs JP¥134 loss in FY 2019) Full year 2020 results: Net loss: JP¥1.11b (loss narrowed 31% from FY 2019). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 14
Full year 2020 earnings released: JP¥68.57 loss per share (vs JP¥134 loss in FY 2019) Full year 2020 results: Net loss: JP¥1.11b (loss narrowed 31% from FY 2019). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings. Duyuru • Feb 12
MedRx Co., Ltd, Annual General Meeting, Mar 26, 2021 MedRx Co., Ltd, Annual General Meeting, Mar 26, 2021. Is New 90 Day High Low • Feb 12
New 90-day high: JP¥291 The company is up 19% from its price of JP¥244 on 13 November 2020. The Japanese market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period. Is New 90 Day High Low • Jan 21
New 90-day high: JP¥272 The company is up 2.0% from its price of JP¥267 on 23 October 2020. The Japanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 15% over the same period. Duyuru • Dec 30
MedRx Co., Ltd to Report Fiscal Year 2020 Results on Feb 10, 2021 MedRx Co., Ltd announced that they will report fiscal year 2020 results on Feb 10, 2021 Is New 90 Day High Low • Dec 09
New 90-day low: JP¥228 The company is down 23% from its price of JP¥297 on 10 September 2020. The Japanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period. Duyuru • Aug 14
MedRx Co., Ltd announced that it has received ¥206.406 million in funding from Japan International Partners LLC On August 13, 2020, MedRx Co., Ltd (TSE:4586) closed the transaction. 